Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Climb Bio, Inc.ELYM · Entity 5064 | EVP and General Counsel | October 31, 2022 | November 02, 2022 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Legal Officer | January 08, 2026 | January 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Climb Bio, Inc.
Report date October 31, 2022 · Filed November 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.27 · Expires 2032-10-30 | Direct | 95,000 |
Reported balance
After 2022-10-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-31 · Grant · Acquired 95,000 · Balance 95,000 F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date.
Zentalis Pharmaceuticals, Inc.
Report date January 08, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2036-01-07 | Direct | 100,000 |
Reported balance
After 2026-01-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-08 · Grant · Acquired 100,000 · Balance 100,000 F1: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALDER BIOPHARMACEUTICALS INC
Report date October 22, 2019 · Filed October 24, 2019
Section 16 reporting ended · disclosed 2019-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-10-22 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-05-31 · Grant · Acquired 1,345 · Balance 11,154 F1: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2019 in a transaction exempt under Rule 16b-3(c). Row 2 · 2019-10-11 · Grant · Acquired 904 · Balance 12,058 F2: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on October 11, 2019 in a transaction exempt under Rule 16b-3(c). Row 3 · 2019-10-22 · Grant · Acquired 15,619 · Balance 27,677 F3: On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 23,429 shares of Issuer's Common Stock (the "RSU"), of which 7,810 shares had vested and the remaining 15,619 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer. The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 6). Row 4 · 2019-10-22 · Other · Disposed 27,677 · Balance 0 F4: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer. F5: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.17 · Expires 2026-03-02 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-10-22 · Disposition to issuer · Disposed 95,000 · Balance 0 F6: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F7: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 18, 2016 (the "2016 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2016 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2016 Vesting Commencement Date. F8: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.40 · Expires 2027-01-26 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-10-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F6: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F8: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. F9: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the "2017 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2017 Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.70 · Expires 2027-12-13 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-10-22 · Disposition to issuer · Disposed 35,000 · Balance 0 F6: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F10: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the "December 2017 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the December 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the December 2017 Vesting Commencement Date F11: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.55 · Expires 2028-02-15 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-10-22 · Disposition to issuer · Disposed 70,000 · Balance 0 F6: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F11: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F12: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "2018 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.24 · Expires 2028-11-24 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-10-22 · Disposition to issuer · Disposed 70,000 · Balance 0 F6: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F11: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F13: 25% of the total number of shares subject to the option shall vest on the one-year anniversary of November 25, 2018 (the "November 2018 Vesting Commencement Date") and thereafter 1/48th of the total number of shares subject to the option shall vest on the monthly anniversary of the November 2018 Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2029-02-05 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-10-22 · Disposition to issuer · Disposed 135,000 · Balance 0 F6: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F11: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F14: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2019 in a transaction exempt under Rule 16b-3(c).
F2: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on October 11, 2019 in a transaction exempt under Rule 16b-3(c).
F3: On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 23,429 shares of Issuer's Common Stock (the "RSU"), of which 7,810 shares had vested and the remaining 15,619 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer. The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 6).
F4: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer.
F5: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.
F6: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck.
F7: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 18, 2016 (the "2016 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2016 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2016 Vesting Commencement Date.
F8: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor.
F9: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the "2017 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2017 Vesting Commencement Date.
F10: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the "December 2017 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the December 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the December 2017 Vesting Commencement Date
F11: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.
F12: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "2018 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date.
F13: 25% of the total number of shares subject to the option shall vest on the one-year anniversary of November 25, 2018 (the "November 2018 Vesting Commencement Date") and thereafter 1/48th of the total number of shares subject to the option shall vest on the monthly anniversary of the November 2018 Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.
F14: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date.
Harpoon Therapeutics, Inc.
Report date March 11, 2024 · Filed March 11, 2024
Section 16 reporting ended · disclosed 2024-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.30 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-11 · Disposition to issuer · Disposed 110,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger (the "Effective Time"), each outstanding option to purchase shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than $23.00 in cash per share of Common Stock, without interest (the "Common Stock Merger Consideration" and each such Stock Option, an F3: (Continued from footnote 2) "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger (the "Effective Time"), each outstanding option to purchase shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than $23.00 in cash per share of Common Stock, without interest (the "Common Stock Merger Consideration" and each such Stock Option, an
F3: (Continued from footnote 2) "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2026 Filed Jan 10, 2026 01:35 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001664928-26-000003 · wk-form4_1768008932.xml · derivative · entry 1 Bucher James B · CIK 0001664928 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-07 F1 · derivative.exercise_date: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| October 01, 2025 Filed Oct 1, 2025 22:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001664928-25-000008 · wk-form4_1759358422.xml · derivative · entry 1 Bucher James B · CIK 0001664928 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2025-09-30 F1 · derivative.exercise_date: The options will vest over a four-year period as follows: 25% of the options will vest on October 1, 2026, with the remaining 75% vesting in substantially equal monthly installments thereafter until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 17:15 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 110,000 | Not disclosed Strike: $11.30 | Not disclosed |
DisclosureSEC source: 0000950170-24-029425 · ownership.xml · derivative · entry 1 Bucher James B · CIK 0001664928 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger (the "Effective Time"), each outstanding option to purchase shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than $23.00 in cash per share of Common Stock, without interest (the "Common Stock Merger Consideration" and each such Stock Option, an F3 · price: (Continued from footnote 2) "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger (the "Effective Time"), each outstanding option to purchase shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than $23.00 in cash per share of Common Stock, without interest (the "Common Stock Merger Consideration" and each such Stock Option, an F3 · derivative.exercise_date: (Continued from footnote 2) "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger (the "Effective Time"), each outstanding option to purchase shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than $23.00 in cash per share of Common Stock, without interest (the "Common Stock Merger Consideration" and each such Stock Option, an F3 · derivative.expiration_date: (Continued from footnote 2) "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 16:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantEmployee Stock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $11.30 | $0.00 |
DisclosureSEC source: 0000950170-23-073031 · ownership.xml · derivative · entry 1 Bucher James B · CIK 0001664928 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2033-12-20 F1 · derivative.exercise_date: 25% of the total number of shares subject to the stock option shall vest and become exercisable on the first anniversary of December 21, 2023, and the remainder vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 19:06 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001209191-22-055400 · doc4.xml · derivative · entry 1 Bucher James B · CIK 0001664928 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2032-10-30 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 17:06 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001209191-22-005630 · doc4.xml · derivative · entry 1 Bucher James B · CIK 0001664928 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2032-01-26 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 19:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053921 · doc4.xml · derivative · entry 10 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135,000 shares Expires 2029-02-05 F6 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F11 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F14 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 19:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001209191-19-053921 · doc4.xml · derivative · entry 9 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2028-11-24 F6 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F11 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F13 · derivative.exercise_date: 25% of the total number of shares subject to the option shall vest on the one-year anniversary of November 25, 2018 (the "November 2018 Vesting Commencement Date") and thereafter 1/48th of the total number of shares subject to the option shall vest on the monthly anniversary of the November 2018 Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 19:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001209191-19-053921 · doc4.xml · derivative · entry 8 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2028-02-15 F6 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F11 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F12 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "2018 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 19:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $10.70 | $0.00 |
DisclosureSEC source: 0001209191-19-053921 · doc4.xml · derivative · entry 7 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2027-12-13 F6 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F10 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the "December 2017 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the December 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the December 2017 Vesting Commencement Date F11 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 19:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-19-053921 · doc4.xml · derivative · entry 6 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2027-01-26 F6 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F8 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. F9 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the "2017 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2017 Vesting Commencement Date. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 19:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $20.17 | $0.00 |
DisclosureSEC source: 0001209191-19-053921 · doc4.xml · derivative · entry 5 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,000 shares Expires 2026-03-02 F6 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F7 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 18, 2016 (the "2016 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2016 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2016 Vesting Commencement Date. F8 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 19:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | OtherCommon Stock | 27,677 | $18.00 | $498,186.00 |
DisclosureSEC source: 0001209191-19-053921 · doc4.xml · nonDerivative · entry 4 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · date: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer. F5 · price: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 19:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantCommon Stock | 15,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053921 · doc4.xml · nonDerivative · entry 3 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,677 F3 · shares: On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 23,429 shares of Issuer's Common Stock (the "RSU"), of which 7,810 shares had vested and the remaining 15,619 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer. The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 6). Read SEC document |
| October 11, 2019 Filed Oct 24, 2019 19:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantCommon Stock | 904 | $9.20 | $8,316.80 |
DisclosureSEC source: 0001209191-19-053921 · doc4.xml · nonDerivative · entry 2 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,058 F2 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on October 11, 2019 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| May 31, 2019 Filed Oct 24, 2019 19:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantCommon Stock | 1,345 | $9.20 | $12,369.97 |
DisclosureSEC source: 0001209191-19-053921 · doc4.xml · nonDerivative · entry 1 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,154 F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2019 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| April 25, 2019 Filed Apr 25, 2019 18:43 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 1,897 | $13.85 | $26,280.85 |
DisclosureSEC source: 0001209191-19-026033 · doc4.xml · nonDerivative · entry 2 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,809 F2 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSU. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 23, 2019 Filed Apr 25, 2019 18:43 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantCommon Stock | 7,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026033 · doc4.xml · nonDerivative · entry 1 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,706 F1 · security: On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 23,429 shares of Issuer's Common Stock (the "RSU"). Up to 7,810 shares subject to the RSU vest upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the "FDA") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the "FDA Filing Milestone") and the remaining shares subject to the RSU vest upon certain other performance criteria. On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 7,810 shares subject to the RSU. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:43 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008565 · doc4.xml · derivative · entry 2 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2029-02-05 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| November 30, 2018 Filed Feb 8, 2019 16:43 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantCommon Stock | 273 | $9.35 | $2,552.55 |
DisclosureSEC source: 0001209191-19-008565 · doc4.xml · nonDerivative · entry 1 Bucher James B · CIK 0001664928 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,896 F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2018 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| November 25, 2018 Filed Nov 27, 2018 17:35 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001209191-18-060011 · doc4.xml · derivative · entry 2 Bucher James B · CIK 0001664928 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-11-24 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option shall vest on the one-year anniversary of November 25, 2018 (the "Vesting Commencement Date") and thereafter 1/48th of the total number of shares subject to the option shall vest on the monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. Read SEC document |
| May 31, 2018 Filed Nov 27, 2018 17:35 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantCommon Stock | 2,000 | $9.35 | $18,700.00 |
DisclosureSEC source: 0001209191-18-060011 · doc4.xml · nonDerivative · entry 1 Bucher James B · CIK 0001664928 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,623 F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2018 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 17:46 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001209191-18-012055 · doc4.xml · derivative · entry 1 Bucher James B · CIK 0001664928 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 18:25 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $10.70 | $0.00 |
DisclosureSEC source: 0001209191-17-066205 · doc4.xml · derivative · entry 2 Bucher James B · CIK 0001664928 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-12-13 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| November 30, 2017 Filed Dec 18, 2017 18:25 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantCommon Stock | 1,623 | $9.35 | $15,175.05 |
DisclosureSEC source: 0001209191-17-066205 · doc4.xml · nonDerivative · entry 1 Bucher James B · CIK 0001664928 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,623 F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2017 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 17:33 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-17-006441 · doc4.xml · derivative · entry 1 Bucher James B · CIK 0001664928 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.